Blood cancers

Perspectives on the use of ibrutinib for relapsed/refractory mantle cell lymphoma: Professor Martin Dreyling

Wednesday, 28 Apr 2021


In this podcast, Professor Martin Dreyling from Germany discusses the role of ibrutinib as standard of care for relapsed or refractory mantle cell lymphoma. He also describes how extended follow-up data for ibrutinib has influenced his treatment decisions.

 

Already a member?

Login to keep reading.

OR
Email me a login link
logo

© 2022 the limbic